Unique ID issued by UMIN | UMIN000006217 |
---|---|
Receipt number | R000007360 |
Scientific Title | Difference in effect on post-meal lipid, proinsulin, GIP and GLP-1 between Sitagliptin, Vildagliptin and Alogliptin in T2DM using DPP-4 inhibitor |
Date of disclosure of the study information | 2011/09/01 |
Last modified on | 2023/05/30 13:55:13 |
Difference in effect on post-meal lipid, proinsulin, GIP and GLP-1 between Sitagliptin, Vildagliptin and Alogliptin in T2DM using DPP-4 inhibitor
Clinical study of DPP-4 inhibitor therapy on post meal lipid, proinsulin, GIP and GLP-1
Difference in effect on post-meal lipid, proinsulin, GIP and GLP-1 between Sitagliptin, Vildagliptin and Alogliptin in T2DM using DPP-4 inhibitor
Clinical study of DPP-4 inhibitor therapy on post meal lipid, proinsulin, GIP and GLP-1
Japan |
Type 2 Diabetes Mellitus
Endocrinology and Metabolism |
Others
NO
To compare the effect of Sitagliptin,Vildagliptin and Alogliptin on metabolic control in patients with type 2 diabetes
Efficacy
Lipid profile(pre-and post-meal(30min,1,2,3hours)triglyceride, pre- and post-meal(30min,1,2,3hours)chylomicron, pre- and post-meal(30min,1,2,3hours)VLDL, pre- and post-meal(30min,1,2,3hours)IDL, pre- and post-meal(30min,1,2,3hours)native LDL, pre- and post-meal(30min,1,2,3hours)small dense LDL, pre- and post-meal(30min,1,2,3hours)HDL
HbA1c, pre- and post-meal blood glucose(30min,1,2,3hours), pre-and post-meal(30min,1,2,3hours)insulin, pre- and post-meal(30min,1,2,3hours)proinsulin, pre- and post-meal(30min,1,2,3hours)C-peptide , pre- and post-meal(30min,1,2,3hours)GLP-1, pre- and post-meal(30min,1,2,3hours)GIP, pre- and post-meal(30min,1,2,3hours)glucagon
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
NO
NO
3
Treatment
Medicine |
Sitagliptin 50mg/day for 3 month
Vildagliptin 100mg/day for 3 month
Alogliptin 25mg/day for 3 month
20 | years-old | <= |
Not applicable |
Male and Female
1)Type 2 Diabetes Mellitus (HbA1c level: more than 6.5%, less tess than 10.0%)
2)Patients with written IC
1)Patients who use of other DPP4 inhibitor
2)Patients who use of fibrate
3)Diabetic neuropathy
4)Severe ketosis,deabetic coma or precoma,type1diabetes
5)Severe renal dysfunction requiring hemodialysis or peritoneal dialysis
6)Severe hepatic dysfunction
7)Patients with a history of hypersensitibity to the study drug
8)Patients before or after operation, and those with severe infections or serious injury
9)Pregnant
10)Patients judged by the investigator to be ineligible for some other reason
30
1st name | |
Middle name | |
Last name | Ikuo Inoue |
Saitama Medical University Hospital
Dept. of Endocrinplogy and Diabetology
38 Morohongo, Moroyama-machi, Iruma-gun, Saitama
049-276-1875
i1901018@saitama-med.ac.jp
1st name | |
Middle name | |
Last name | Ikuo Inoue |
Saitama Medical University Hospital
Dept. of Endocrinplogy and Diabetology
38 Morohongo, Moroyama-machi, Iruma-gun, Saitama
049-276-1875
i1901018@saitama-med.ac.jp
Saitama Medical University
None
Self funding
Kumagaya Geka Hospital
None
NO
埼玉医科大学(埼玉県)
熊谷外科病院(埼玉県)
2011 | Year | 09 | Month | 01 | Day |
Partially published
Completed
2011 | Year | 08 | Month | 24 | Day |
2011 | Year | 08 | Month | 24 | Day |
2011 | Year | 09 | Month | 01 | Day |
2012 | Year | 07 | Month | 01 | Day |
2011 | Year | 08 | Month | 23 | Day |
2023 | Year | 05 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007360